Unichem Laboratories spurted 4.44% to Rs 331.90 after the company said it received tentative approval for ANDA of aripiprazole tablets from the US drug regulator.
Aripiprazole tablets are a generic version of Abilify of Otsuka Pharmaceutical Co. The drug is indicated for Schizophrenia, Irritability Associated with Autistic Disorder and treatment of Tourette's disorder. Product will be commercialized from Unichem's Ghaziabad plant on receipt of full approval.The company reported a consolidated net loss of Rs 0.41 crore in Q4 FY21 as compared to a net loss of Rs 17.19 crore in Q4 FY20. Net sales during the quarter decreased 5.5% Y-o-Y (year-on-year) to Rs 274.12 crore.
Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app